Screener
Oruka Therapeutics, Inc. ORKA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -27.3%+58.0pp | -24.7%+42.9pp | -38.5%-7.4pp | —— | -85.3%-30.7pp | |
| Return on invested capital | -37%— | -32.6%— | -50.1%— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 23.8×-6.3× | 22.4×-6.5× | 16.9×-6.0× | 27.4×+0.8× | 30×+30.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | 0×-48.0× | |
| Valuation | ||||||
| Market capitalization | $5.52B+495% | $1.47B+116% | $930.43M— | $440.3M— | $384.14M— | |
| Price / book | 11.3×+9.4× | 3.1×+1.3× | 1.9×— | 1.3×— | 1.1×— |
FAQ
- Where do Oruka Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Oruka Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.